CDK5 and early-onset autosomal dominant Alzheimer disease: The same method was used in ref (218) to assess the binding strength of nine ligands,organized into two subgroups, of the cyclin-dependent kinase-5 (CDK5)enzyme, which promotes the hyperphosphorylation of the tau protein,and thus could be a target for drugs to treat Alzheimer’s disease,multiple sclerosis, Parkinson’s disease, amyotrophic lateralsclerosis, etc. Kinase proteins are a difficult target for steeredMD because of the simultaneous presence of a solvent-exposed activesite and marked flexibility at the same binding site.